Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Elicio Therapeutics, Inc. has 10 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Elicio Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We also have an exclusive license from Dr. Roberto Chiarle for a patent family titled "Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination," which contains two granted U.S. patents.”
FILING10-K0001601485-26-000027cik 0001601485
“We received funding for the initial development of ELI-007 through three grants from the Gastro-Intestinal ("GI") Research Foundation.”
FILING10-K0001601485-26-000027cik 0001601485
“We currently have no other commitments or agreements relating to any of these 38 Table of Contents types of transactions, other than the Note Purchase Agreement, dated June 3, 2025, between us and GKCC, LLC ("GKCC") and the related Senior Secured Promissory Note due June 3, 2028 held by GKCC, our Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC and obligations related to the exercise of previously issued warrants, and cannot be certain that additional funding will be available to us on acceptable terms, or at all.”
FILING10-K0001601485-26-000027cik 0001601485
“On January 27, 2016, we entered into an Exclusive Patent License Agreement with Massachusetts Institute of Technology ("MIT"), which has been amended from time to time (the "MIT License Agreement").”
FILING10-K0001601485-26-000027cik 0001601485
“In September 2025, we announced an Investigator-Initiated Phase 1 Trial ("IIT") to be conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in PDAC.”
FILING10-K0001601485-26-000027cik 0001601485
“In September 2025, we announced an Investigator-Initiated Phase 1 Trial ("IIT") to be conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in PDAC.”
FILING10-K0001601485-26-000027cik 0001601485
“In March 2024, we entered into a subscription agreement (the "March Subscription Agreement") with GKCC, LLC ("GKCC"), an entity controlled by a member of Elicio's board of directors, providing for the issuance and sale by Elicio to GKCC of pre-funded warrants (the "March 2024 Pre-Funded Warrants") to purchase up to 1,032,702 shares of common stock, at a purchase price per March 2024 Pre-Funded Warrant of $5.81 (the "March 2024 Offering").”
FILING10-K0001601485-26-000027cik 0001601485
“The pending application directed to the mutant BRAF-driven cancer program is co-owned by Cornell University.”
FILING10-K0001601485-26-000027cik 0001601485
“We currently have no other commitments or agreements relating to any of these 38 Table of Contents types of transactions, other than the Note Purchase Agreement, dated June 3, 2025, between us and GKCC, LLC ("GKCC") and the related Senior Secured Promissory Note due June 3, 2028 held by GKCC, our Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC and obligations related to the exercise of previously issued warrants, and cannot be certain that additional funding will be available to us on acceptable terms, or at all.”
FILING10-K0001601485-26-000027cik 0001601485
“Simultaneously, we entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC, as sales agents, that provided for the issuance and sale of up to $21 million of shares of common stock from time to time in "at-the-market" offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the "2022 ATM Program").”
FILING10-K0001601485-26-000027cik 0001601485
“Simultaneously, we entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC, as sales agents, that provided for the issuance and sale of up to $21 million of shares of common stock from time to time in "at-the-market" offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the "2022 ATM Program").”
FILING10-K0001601485-26-000027cik 0001601485
Watchlist prices, news filtered to it, and its next report on your desk.
Elicio Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
ELTX (Elicio Therapeutics, Inc.) has 10 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Prev close 1.99 · gapped below the open, then crossed back over prior close. High/low 2.02 at 4:30 pm ET, 1.94 at 9:45 am ET.